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In this issue of JEM, Thierry et al. (https:// doi .org/ 10 .1084/ jem .20180344) demonstrate that, once secreted by freshly activated 
plasmablasts, IgM leaves the lymph node via the microarchitecture of the fibroblastic reticular cell conduit. This work 




The release of IgM is the first line of an 
antibody response and precedes the gen-
eration of high affinity IgG in germinal 
centers. Once secreted by freshly activated 
plasmablasts, IgM is released into the effer-
ent lymph of reactive lymph nodes as early 
as 3 d after immunization. As pentameric 
IgM has an enormous size of 1,000 kD, its 
diffusibility is low, and one might wonder 
how it can pass through the densely lym-
phocyte-packed environment of a lymph 
node parenchyma in order to reach its exit. 
In this issue of JEM, Thierry et al. show 
that, in order to reach the blood stream, 
IgM molecules take a specific micro-ana-
tomical route via lymph node conduits.
The conduit system, the interstitial com-
partment of secondary lymphatic organs, is 
the site where extracellular matrix (ECM) 
molecules (collagens, glycans, etc.) consti-
tute the architecture through which solute 
extracellular signaling molecules or plasma 
components move. However, the intersti-
tium of lymphatic organs is substantially 
different from other mesenchymal tissues, 
as it is extremely compacted, to an extent 
that it does not surround its producing cells. 
The lymphatic fibroblasts, called fibroblas-
tic reticular cells (FRCs), rather enwrap the 
ECM, which is organized in a 3D meshwork 
of thin strands with a diameter <1 µm. The 
functional unit of the FRC and its ECM has 
been termed FRC conduit because it acts like 
a microvascular network transecting the 
lymph node parenchyma. Conduits com-
municate with afferent lymph in the sub-
capsular sinus as well as the lumen of blood 
vessels, and tracer studies showed that con-
duits not only represent the preferred route 
of solutes but also act as a molecular sieve. 
They selectively channel solutes <70 kD in 
size from the afferent lymph into the blood 
vessel lumen. Larger substances do not have 
access to the conduit system and use the 
lymphatic sinuses to bypass the lymph node 
parenchyma. They travel via the efferent 
lymph and the thoracic duct back into the 
blood. Hence, the lymph node is a two-level 
filter for interstitial fluid: large molecules 
pass through the sinus into the efferent 
lymph. Small solutes pass via the conduit 
system directly into the blood (Malhotra et 
al., 2013).
Thierry et al. (2018) started off by immu-
nostaining lymph nodes of freshly immu-
nized mice when they are at the peak of an 
IgM response. They found that IgM localizes 
in a reticular pattern, and by costaining 
with ECM components and reporters for 
FRCs combined with electron microscopy, 
they found that IgM localizes in the lumen 
of conduits. Wondering how it got there, the 
authors considered two possibilities: either 
IgM is already in the systemic circulation 
and enters the lymph node reversely via the 
blood or the lymph, or it is locally produced 
in reactive lymph nodes and accesses con-
duits from within the parenchyma—mean-
ing that IgM is on its way out of the node. 
A decisive hint arguing against the systemic 
option came from the fact that IgM was only 
found in conduits of the lymph node drain-
ing the site of inoculation, but not in others. 
When the authors injected IgM containing 
serum into Ig-deficient mice via different 
routes (blood and lymph), the assumption 
was confirmed, and IgM did not reach the 
conduit compartment via the lymph (sub-
cutaneous injection) or via the blood (intra-
venous injection). The only maneuver that 
led to the reticular localization pattern was 
injecting IgM directly into the lymph node 
parenchyma, and the same was true for in-
jecting other high molecular weight tracer 
molecules. These data were in line with pre-
vious tracer studies showing that large mol-
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ecules do not have access to conduits via the 
afferent lymphatic route and that there is 
generally no flux of solutes (not even small 
ones) from the blood into the lymph node 
conduits (Gretz et al., 2000). This finding, 
that upon parenchymal injection IgM enters 
the conduits, is noteworthy for two reasons. 
(1) The size-exclusion phenomenon of the 
conduit system was often compared with a 
gel filtration-like function of the ECM that 
sieves out larger components (Gretz et al., 
1997). However, a recent paper located the 
site of size exclusion to the conduit entry 
sites in the subcapsular sinus, where an-
atomical structures morphologically and 
molecularly similar to endothelial fenestra-
tions regulate entry (Rantakari et al., 2015). 
Thierry et al. (2018) find that large mole-
cules also locate to conduits when directly 
injected into the parenchyma, thus confirm-
ing that the sieve is not the conduit itself but 
must be at its interface with the subcapsular 
sinus. (2) Previous studies argued that the 
conduit system resembles a rather closed 
“micro-vascular” compartment. In such a 
scenario only some cells, mainly dendritic 
cells and macrophages, which are embedded 
into the FRC layer or stick protrusions into 
the conduit lumen, have access to the filtrate 
(Catron et al., 2004). Based on the findings 
by Thierry et al. (2018), it seems likely that 
within the parenchyma, the conduit system 
is not hermetic but openly communicates 
with the interstitial space between the lym-
phocytes. Nevertheless, the drainage route 
of IgM argued that the preferred site of sol-
ute transport is the conduit system. Hence, 
it seems likely that the FRC conduit rather 
acts like a river delta or an open drainage 
system than a closed pipe system: it freely 
communicates with the interstitial space 
between the lymphocytes but acts as a col-
lector to drain fluid and solutes.
After applying IgM externally, which 
might perturb the potentially delicate archi-
tecture and physiology of the lymph node, 
the authors also devised two sophisticated 
genetic approaches to demonstrate that en-
dogenous IgM also enters conduits during 
immunologically relevant responses. They 
created two mouse models where IgM is pro-
duced either in response to antigenic vacci-
nation or to viral infection. Due to genetic 
mismatches, freshly produced antigen-spe-
cific IgM could be selectively detected in 
situ. Both models confirmed the initial 
finding: once produced by the plasmablast, 
IgM is not only located on the surface of the 
producing cells but also within the conduit 
system. This adds compelling evidence that 
for IgM, the conduit system is the preferred 
drainage route out of the lymph node.
The work of Thierry et al. (2018) allocates 
a very plausible function to an anatomical 
structure that is still poorly understood. Ini-
Upper panel: Upon immunization or infection, IgM locates to the draining lymph nodes conduit system. The 
∼1,000-kD pentameric antibody is produced locally by plasmablasts during the early phase of infection (i.e., 
4 d). The conduit system, composed of FRCs surrounding a network of ECM molecules such as collagens, 
allows the fast transport of secreted IgM toward the medullary sinus and the high endothelial venules. IgM 
transported by the afferent lymphatics cannot access the lymph node parenchyma due to the subcapsular 
sinus acting as a molecular sieve; instead, IgM arriving with the afferent lymph are channeled via the sub-
capsular sinus around the parenchyma of the lymph node and enter the blood circulation via the thoracic 
duct. Lower panel: Two possible paths of IgM into conduit lumen. (1) A hydrostatic pressure gradient be-
tween lymph node parenchyma and conduit drives fluid and its solutes into the lumen of the conduit. (2) 
IgM-secreting plasmablasts can migrate, actively couple to FRCs, and directly secrete their antibodies into 
the conduit system.
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tial work on the conduit system led to the as-
sumption that it might primarily serve as an 
input system, where peripherally produced 
cytokines, chemokines, and antigens that 
arrive with the afferent lymph get chan-
neled to resident dendritic cells, B cells, and 
also into the lumen of high endothelial ve-
nules. The findings of Thierry et al. (2018) 
suggest that conduits also have an output 
function by allowing substances to leave 
the lymph node. This adds to a previous 
study, which showed that upon peripheral 
bacterial infection, a fragment of the ECM 
protein Cochlin is cleaved from the lumen 
of conduits and released into the periph-
ery, where it serves to amplify cytokine re-
sponses (Py, 2013).
Mechanistically, many open questions re-
main. How does IgM travel from the plasma- 
blast into the conduit lumen? Thierry et al. 
(2018) contemplate two possibilities. (1) The 
migratory plasmablast may actively estab-
lish physical contact with the conduit and 
directly secrete IgM into its lumen. (2) The 
plasmablast secretes into the parenchyma, 
and IgM follows a fluid current along a hy-
drostatic pressure gradient that drains into 
the conduit. From the conduit, IgM might 
then directly enter the blood circulation 
(most likely via drainage into high endo-
thelial venules) or be discharged into the 
medullary sinus, from where it reaches the 
blood circulation via the efferent lymph 
and the thoracic duct. To better understand 
these important processes, it will be essen-
tial to test basic physiological parameters 
of the homeostatic and the inflamed lymph 
node. What are the forces driving fluid and 
its solutes through the conduit system? In 
peripheral tissues, fluid exchange between 
vasculature and interstitium is driven by 
Starling forces—the difference between 
osmotic suction and hydrostatic pressure 
across the vessel wall (Levick and Michel, 
2010). Is the same true in lymphatic organs, 
where the interstitium is organized in such a 
peculiar way? Or is there another force driv-
ing flux within the conduits? Interestingly, 
the conduits of the spleen and the thymus, 
organs that lack the additional fluid supply 
by afferent lymphatics, are filled “retro-
gradely” via the blood, probably meaning 
that the blood vessels of these organs are in a 
state of constant fluid secretion, as opposed 
to the fluid-resorbing state of the lymph 
node blood circulation. Could lymph nodes 
also switch to this mode, e.g., when venous 
pressure increases, the osmotic state of the 
lymph node parenchyma changes, or when 
the muscular tone of blood vessels or con-
duits is tuned? None of these parameters 
have been studied, but they might have pro-
found implications for the orchestration and 
regulation of adaptive immune responses.
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